These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 18957950)

  • 21. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
    Strippoli GF; Tong A; Palmer SC; Elder G; Craig JC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD006254. PubMed ID: 17054287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.
    Lindberg JS
    Kidney Int Suppl; 2005 Jun; (95):S33-6. PubMed ID: 15882311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.
    Rodríguez M; Goodman WG; Liakopoulos V; Messa P; Wiecek A; Cunningham J
    Semin Dial; 2015; 28(5):497-507. PubMed ID: 25752650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcium-sensing receptor activation in chronic kidney disease: effects beyond parathyroid hormone control.
    Massy ZA; Hénaut L; Larsson TE; Vervloet MG
    Semin Nephrol; 2014 Nov; 34(6):648-59. PubMed ID: 25498383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ; Slatopolsky E
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical experience with cinacalcet HCl.
    Ureña Torres P
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V27-33. PubMed ID: 15284357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitamin D receptor activation and survival in chronic kidney disease.
    Kovesdy CP; Kalantar-Zadeh K
    Kidney Int; 2008 Jun; 73(12):1355-63. PubMed ID: 18288097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.
    Kalantar-Zadeh K; Shah A; Duong U; Hechter RC; Dukkipati R; Kovesdy CP
    Kidney Int Suppl; 2010 Aug; (117):S10-21. PubMed ID: 20671739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
    de Francisco AL
    Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
    Stubbs J; Liu S; Quarles LD
    Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vitamin D treatment in chronic kidney disease.
    Andress DL
    Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcimimetics versus vitamin D: what are their relative roles?
    Drüeke TB
    Blood Purif; 2004; 22(1):38-43. PubMed ID: 14732810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology].
    Mazzaferro S; Cozzolino M; Marangella M; Strippoli GF; Messa P;
    G Ital Nefrol; 2007; 24 Suppl 37():S107-24. PubMed ID: 17347960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.
    Cannata-Andía JB; Rodriguez-García M; Román-García P; Tuñón-le Poultel D; López-Hernández F; Rodríguez-Puyol D
    Pediatr Nephrol; 2010 Apr; 25(4):609-16. PubMed ID: 20151157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcimimetics in the chronic kidney disease-mineral and bone disorder.
    Bover J; Aguilar A; Baas J; Reyes J; Lloret MJ; Farré N; Olaya M; Canal C; Marco H; Andrés E; Trinidad P; Ballarin J
    Int J Artif Organs; 2009 Feb; 32(2):108-21. PubMed ID: 19363783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary hyperparathyroidism (CKD-MBD) treatment and the risk of dementia.
    Mathur A; Ahn JB; Sutton W; Chu NM; Gross AL; Segev DL; McAdams-DeMarco M
    Nephrol Dial Transplant; 2022 Oct; 37(11):2111-2118. PubMed ID: 35512551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.
    Sprague SM; Coyne D
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):512-8. PubMed ID: 20133492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Basic and clinical aspects of calcimimetics. The pathogesis and treatment of secondary hyperparathyroidism].
    Mizobuchi M; Akizawa T
    Clin Calcium; 2008 Jan; 18(1):13-9. PubMed ID: 18175866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.